London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director. Dr Gittleson has extensive...
Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research. Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such...
Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for non-communicable diseases. US FDA grants IND authorization to commence Phase III trials with triple combination candidate for the treatment of hypertension. Chief Business Officer, Karl Roberts, appointed to new role of...
Differences in how blood pressure affects the risk of dementia in men and women may provide clues to help slow the rapid growth of the disease, according to new research published today. In a study of just over half a million people, George Institute researchers found...
When clinical trials become a normal part of care options for patients with unmet needs, both researchers and patients will reap exponential rewards. “Where are the patients?” Clinical trials hinge on recruitment, and enrollment issues are a perpetual challenge. Research estimates that, on average, around 20-25%...
The George Institute for Global Health is delighted to announce the launch of The Scan, a new podcast exploring the latest research, emerging evidence, and progress towards improving health outcomes in non-communicable diseases and injury around the world. Each episode of The Scan will deep dive into a new...
Dr. Adrian Liew, a nephrologist and scientific leader with George Clinical, was the recipient of the 2020 International Society for Peritoneal Dialysis Congress John Maher Award, honoring young individuals who have contributed substantially to the field of peritoneal dialysis (PD). Maher was a great contributor...
Around half a billion people worldwide have diabetes and up to 40% will go onto develop kidney disease. The global cost of treating diabetes is estimated at almost US$830 billion per year. The lack of access to costly dialysis treatment for kidney failure kills several million...
The AustralaSian COVID-19 Trial (ASCOT) has been expanded into India, with the first patients recruited to the first two sites, Christian Medical College and Hospital Ludhiana in Punjab and Sterling Multispecialty Hospital in Pune, Maharashtra. ASCOT aims to discover which existing treatments are most effective in patients...
An innovative study to assess whether a commonly used cholesterol lowering medication can prevent brain complications from COVID-19 has received over $2.3m from the Government’s Medical Research Future Fund. The study, a collaboration between The George Institute for Global Health, the University of New South Wales,...
“Extraordinary achievements under unprecedented conditions,” is how Chief Medical Officer Maria Ali describes the reality of a George Clinical team drawing on proven working models, established global relationships and an unflinching dedication to implement a clinical trial in a matter of weeks during a global...
A new Australian product designed to make kidney dialysis more broadly available at low cost has won first prize in a global health innovations competition. The Affordable Dialysis System, developed by Sydney-based Ellen Medical, beat more than 500 entries from 43 countries to score top prize...
Affordable dialysis worldwide: Q+A with John Knight of Ellen Medical Devices about the world’s first low-cost dialysis system. Professor John Knight, a children’s kidney specialist, is the Managing Director of Ellen Medical Devices and a senior researcher at The George Institute for Global Health. He speaks...
$53 million cash injection from Australian investors - one of the country’s largest-ever private-public health partnerships. Funds set to accelerate research and development by George Health and George Medicines – companies established by one of the world’s leading medical research institutes. Sydney, Australia, March 10 – The...